Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Erlotinib or Alectinib in Patients With Advanced Non-Small Cell Lung Cancer

NCT02013219 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02013219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02013219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Erlotinib or Alectinib in Patients With Advanced Non-Small Cell Lung Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
April 3, 2014
Completion date
February 5, 2020
Enrollment
52 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer